Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cepharanthine is a natural bisbenzylisoquinoline alkaloid extracted from the plant Stephania cepharantha Hayata. It has been used in Japan since the 1950s to treat a variety of acute and chronic diseases, including radiation-induced leukopenia, alopecia areata, idiopathic thrombocytopenic purpura, venomous snakebites, xerostomia, sarcoidosis, refractory anemia, and various cancer-related conditions. Cepharanthine exhibits anti-inflammatory, immunomodulatory, antineoplastic (anticancer), antiviral (including activity against HSV and HIV in vitro), anti-parasitic and antioxidative properties[1][5][7][8]. Its mechanism of action is multifactorial: it modulates membrane efflux pumps and rigidifies membranes; intracellularly it activates AMP-activated protein kinase (AMPK) and inhibits NFκB signaling pathways—leading to reduced inflammation—and can also inhibit PI3K/Akt and p38 MAPK signaling pathways involved in cell proliferation and survival[1][6][8]. Cepharanthine can induce cell cycle arrest at G2/M phase and promote apoptosis in infected or malignant cells. It is approved for use primarily in Japan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cepharanthine.